<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1316">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04532294</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-DXP593-101</org_study_id>
    <nct_id>NCT04532294</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants</brief_title>
  <official_title>A First-in-Human, Randomized, Double-Blind, Placebo Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to investigate the safety and tolerability of BGB-DXP593
      administered intravenously as a single dose in healthy participants
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to 113 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 113 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BGB-DXP593</measure>
    <time_frame>Up to 113 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) from time zero to the time of the last quantifiable concentration (AUCt) of BGB-DXP593</measure>
    <time_frame>Up to 113 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from time zero to infinity (AUCinf) of BGB-DXP593</measure>
    <time_frame>Up to 113 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from time zero to Day 29 (AUC0-29) of BGB-DXP593</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed plasma concentration (tmax) of BGB-DXP593</measure>
    <time_frame>Up to 113 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half life (t1/2) of BGB-DXP593</measure>
    <time_frame>Up to 113 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of BGB-DXP593</measure>
    <time_frame>Up to 113 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vz) of BGB-DXP593</measure>
    <time_frame>Up to 113 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenic response to BGB-DXP593 as assessed by the Detection of antidrug antibodies (ADA)</measure>
    <time_frame>Up to 113 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>BGB-DXP593: Dose Level A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive BGB-DXP593 10 mg/kg on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo: Dose Level A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive placebo to match (PTM) BGB-DXP593 10 mg/kg on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BGB-DXP593: Dose Level B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive BGB-DXP593 30 mg/kg on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo: Dose Level B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive placebo to match (PTM) BGB-DXP593 30 mg/kg on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BGB-DXP593: Dose Level C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BGB-DXP593 at a higher dose determined from the two previous dose levels on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo: Dose Level C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo to match (PTM) BGB-DXP593 at a higher dose determined from the two previous dose levels on Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB DXP593</intervention_name>
    <description>Administered intravenously (IV) as specified in the treatment arm</description>
    <arm_group_label>BGB-DXP593: Dose Level A</arm_group_label>
    <arm_group_label>BGB-DXP593: Dose Level B</arm_group_label>
    <arm_group_label>BGB-DXP593: Dose Level C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match BGB-DXP593</description>
    <arm_group_label>Placebo: Dose Level A</arm_group_label>
    <arm_group_label>Placebo: Dose Level B</arm_group_label>
    <arm_group_label>Placebo: Dose Level C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria :

          1. Participants are in good general health as determined by the investigator or medically
             qualified designee, based on a medical evaluation including medical history, physical
             examination, laboratory tests and cardiac monitoring

          2. Body weight â‰¥ 50 kg and body mass index (BMI) within the range 18 to 32 kg/m2
             (inclusive) Note: BMI = weight [kg] / (height [m])

          3. Negative serum IgM and IgG to the SARS-CoV-2

          4. Negative for COVID-19 based on the nasopharyngeal or oropharyngeal swab with the
             method of real-time reverse transcription-polymerase chain reaction (rRT-PCR)

        Key Exclusion Criteria:

          1. History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal,
             endocrinological, hematological, or neurological disorders capable of significantly
             altering the absorption, metabolism, or elimination of drugs, constituting a risk to
             the participant when taking the study drug; or interfering with the interpretation of
             data

          2. Any history of a severe allergic reaction prior to enrollment that has a reasonable
             risk of recurrence during the study

          3. Have a medical history of SARS infection

          4. Any acute fever disease or infections

          5. Any chronic or clinically significant medical condition that, in the opinion of the
             investigator, would jeopardize the safety or rights of the participant, including but
             not limited to: diabetes mellitus type I, chronic hepatitis; or clinically significant
             forms of: drug or alcohol abuse, asthma (except for childhood asthma), autoimmune
             disease, psychiatric disorders, or heart disease

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhen Yao</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>+1 877 828 5568</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Q Pharm Pty Limited</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>September 13, 2020</last_update_submitted>
  <last_update_submitted_qc>September 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

